Elacestrant Impresses in EMERALD Trial of Breast Cancer

EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer

Clinical Trials for Metastatic HER2-positive Breast Cancer

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

Elacestrant Impresses in EMERALD Trial of Breast Cancer

Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Forefront Breaking News

EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting